161 related articles for article (PubMed ID: 26759696)
1. NDRG2 Expression Decreases Tumor-Induced Osteoclast Differentiation by Down-regulating ICAM1 in Breast Cancer Cells.
Kim B; Nam S; Lim JH; Lim JS
Biomol Ther (Seoul); 2016 Jan; 24(1):9-18. PubMed ID: 26759696
[TBL] [Abstract][Full Text] [Related]
2. Regulation of tumor-associated macrophage (TAM) differentiation by NDRG2 expression in breast cancer cells.
Lee S; Lee A; Lim J; Lim JS
BMB Rep; 2022 Feb; 55(2):81-86. PubMed ID: 34743782
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of osteoclast differentiation by overexpression of NDRG2 in monocytes.
Kang K; Nam S; Kim B; Lim JH; Yang Y; Lee MS; Lim JS
Biochem Biophys Res Commun; 2015 Dec; 468(4):611-6. PubMed ID: 26546825
[TBL] [Abstract][Full Text] [Related]
4. NDRG2 correlated with favorable recurrence-free survival inhibits metastasis of mouse breast cancer cells via attenuation of active TGF-β production.
Oh SS; Kim D; Kim DH; Chang HH; Sohn KC; Kim KH; Jung SH; Lee BK; Kim JH; Kim KD
Carcinogenesis; 2012 Oct; 33(10):1882-8. PubMed ID: 22696597
[TBL] [Abstract][Full Text] [Related]
5. Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.
Lee JH; Kim B; Jin WJ; Kim JW; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2014 Sep; 91(1):51-60. PubMed ID: 24929117
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells development into osteoclast-type APCs by 4T1 breast tumor T cells milieu boost bone consumption.
Monteiro AC; Bonomo A
Bone; 2021 Feb; 143():115755. PubMed ID: 33217627
[TBL] [Abstract][Full Text] [Related]
7. Loss of NDRG2 in liver microenvironment inhibits cancer liver metastasis by regulating tumor associate macrophages polarization.
Li M; Lai X; Zhao Y; Zhang Y; Li M; Li D; Kong J; Zhang Y; Jing P; Li H; Qin H; Shen L; Yao L; Li J; Dou K; Zhang J
Cell Death Dis; 2018 Feb; 9(2):248. PubMed ID: 29445150
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Hussein O; Tiedemann K; Komarova SV
Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
[TBL] [Abstract][Full Text] [Related]
9. Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation.
Bolin C; Tawara K; Sutherland C; Redshaw J; Aranda P; Moselhy J; Anderson R; Jorcyk CL
Genes Cancer; 2012 Feb; 3(2):117-30. PubMed ID: 23050044
[TBL] [Abstract][Full Text] [Related]
10. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
11. Suppression of N-myc downstream-regulated gene 2 is associated with induction of Myc in colorectal cancer and correlates closely with differentiation.
Shi H; Jin H; Chu D; Wang W; Zhang J; Chen C; Xu C; Fan D; Yao L
Biol Pharm Bull; 2009 Jun; 32(6):968-75. PubMed ID: 19483300
[TBL] [Abstract][Full Text] [Related]
12. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
[TBL] [Abstract][Full Text] [Related]
13. N-myc downstream-regulated gene 2 (NDRG2) suppresses the epithelial-mesenchymal transition (EMT) in breast cancer cells via STAT3/Snail signaling.
Kim MJ; Lim J; Yang Y; Lee MS; Lim JS
Cancer Lett; 2014 Nov; 354(1):33-42. PubMed ID: 25153349
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts.
Grano M; Mori G; Minielli V; Cantatore FP; Colucci S; Zallone AZ
Biochem Biophys Res Commun; 2000 Apr; 270(3):1097-100. PubMed ID: 10772956
[TBL] [Abstract][Full Text] [Related]
15. Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis.
Takemori T; Kawamoto T; Ueha T; Toda M; Morishita M; Kamata E; Fukase N; Hara H; Fujiwara S; Niikura T; Kuroda R; Akisue T
Oncol Rep; 2018 Oct; 40(4):2079-2087. PubMed ID: 30066936
[TBL] [Abstract][Full Text] [Related]
16. Expression and regulation of NDRG2 (N-myc downstream regulated gene 2) during the differentiation of dendritic cells.
Choi SC; Kim KD; Kim JT; Kim JW; Yoon DY; Choe YK; Chang YS; Paik SG; Lim JS
FEBS Lett; 2003 Oct; 553(3):413-8. PubMed ID: 14572661
[TBL] [Abstract][Full Text] [Related]
17. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems.
Liverani C; Mercatali L; Spadazzi C; La Manna F; De Vita A; Riva N; Calpona S; Ricci M; Bongiovanni A; Gunelli E; Zanoni M; Fabbri F; Zoli W; Amadori D; Ibrahim T
Bone; 2014 Sep; 66():214-22. PubMed ID: 24956020
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer cell-derived fibroblast growth factors enhance osteoclast activity and contribute to the formation of metastatic lesions.
Aukes K; Forsman C; Brady NJ; Astleford K; Blixt N; Sachdev D; Jensen ED; Mansky KC; Schwertfeger KL
PLoS One; 2017; 12(10):e0185736. PubMed ID: 28968431
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.
Knowles HJ; Athanasou NA
J Pathol; 2008 May; 215(1):56-66. PubMed ID: 18283716
[TBL] [Abstract][Full Text] [Related]
20. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity.
Pederson L; Winding B; Foged NT; Spelsberg TC; Oursler MJ
Cancer Res; 1999 Nov; 59(22):5849-55. PubMed ID: 10582709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
